Derma Sciences Ships First MEDIHONEY over-the-counter Product to Leading U.S. Pharmacy Chain
Derma Sciences Ships First MEDIHONEY over-the-counter Product to Leading U.S. Pharmacy Chain
Brings private-label honey-based dressing to more than 4,000 stores nationwide
PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (NAS: DSCI) , a medical device and pharmaceutical company focused on advanced wound care, today reported that it has made an initial shipment of its first honey-based over-the-counter (OTC) product to a leading U.S.-based pharmacy chain. This private-label dressing is based on the MEDIHONEY HCS dressing, which is an ideal dressing for dry to lightly exuding wounds including minor burns, cuts and abrasions. The dressing is expected to be on the shelves in more than 4,000 stores by the end of September. This OTC dressing is expected to add approximately $1.2 million to Derma Sciences' traditional wound care sales in the second half of 2013.
"The development of an OTC honey-based dressing is an important achievement for Derma Sciences and is indicative of our ability to modify our advanced wound care products to the consumer market," said Edward J. Quilty, Derma Sciences chairman and chief executive officer. "We are thrilled that this large pharmacy chain has recognized the quality of our products and are excited to offer this innovative dressing, our first honey-based OTC dressing, to the broader market."
As part of the private-label supply agreement, Derma Sciences will be working with the pharmacy chain to encourage adoption and utilization. The company will launch a similar dressing into the professional market during the fourth quarter in order to create initial awareness and demand within the hospital setting, and then educate patients and caregivers to the product's availability within the retail pharmacy setting.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products; advanced wound care dressings to address chronic wounds including diabetic ulcers; and traditional dressings. The Company has begun its Phase 3 clinical trial in diabetic foot ulcer healing with DSC127, based on excellent Phase 2 data. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention.
For more information please visit www.dermasciences.com.
Forward-Looking Statements
Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.
Derma Sciences, Inc.
Barry Wolfenson
Group President, Advanced Wound Care and Pharmaceutical Development
(609) 514-4744
bwolfenson@dermasciences.com
or
LHA
Kim Sutton Golodetz, (212) 838-3777
kgolodetz@lhai.com
Bruce Voss, (310) 691-7100
bvoss@lhai.com
KEYWORDS: United States North America New Jersey
INDUSTRY KEYWORDS:
The article Derma Sciences Ships First MEDIHONEY over-the-counter Product to Leading U.S. Pharmacy Chain originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
